Taken together, our RNA expression data suggest that class IIa HDAC inhibition is beneficial for the treatment of head and neck cancers possibly by modulating the expression of genes whose up- or downregulation is known from Kaplan–Meier data to positively affect head–neck cancer patient survival. The gene discussed is HDAC9; the disease is head and neck cancer.